GPhA: State Biosimilar Laws Could Have ‘Chilling Effect’

Brand drugmakers are pushing states to enact legislation that could create hurdles for biosimilar substitution — a business move designed to hold on to profits, GPhA says. Amgen and Genentech have been pushing state legislators to enact measures, including a bill currently making its way through Virginia’s General Assembly that could have a chilling effect on biosimilar substitution because it requires pharmacists to notify prescribers that an interchangeable biosimilar is being doled out to the patient, GPhA said.
Washington Drug Letter